Exclusion Criteria – Any of the following prevents coverage

Concurrent use of organic nitrates

POLICY NAM	Revatio (sildenafil)	POLICY #	1976P
Criteria			
Coverage Criteria for Pulmonary Arterial Hypertension (PAH)			
☐ See Pulmonary Arterial Hypertension products policy			
	riteria for Raynaud Phenomenon is of Raynaud's Phenomenon		
	•		
☐ Documented inadequate response to a Calcium Channel Blocker (CCB; such as amlodipine)			
Docume	nted failure to respond, intolerance, or contraindication	on to topical nitrates	
☐ Covera	e of Revatio requires a documented allergic reaction	to generic sildenafil	